Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) has earned a consensus recommendation of “Hold” from the six ratings firms that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $2.63.
Several analysts have commented on SYN shares. HC Wainwright started coverage on shares of Synthetic Biologics in a research report on Friday. They set a “buy” rating for the company. Zacks Investment Research upgraded shares of Synthetic Biologics from a “sell” rating to a “buy” rating and set a $0.25 target price for the company in a research report on Saturday, May 12th. Finally, Griffin Securities cut shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 9th.
Get Synthetic Biologics alerts:
Shares of Synthetic Biologics opened at $0.25 on Friday, Marketbeat.com reports. Synthetic Biologics has a 52 week low of $0.23 and a 52 week high of $0.27.
Synthetic Biologics (NYSEAMERICAN:SYN) last issued its earnings results on Tuesday, May 8th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.03.
Several institutional investors and hedge funds have recently added to or reduced their stakes in SYN. Citadel Advisors LLC boosted its stake in Synthetic Biologics by 312.1% in the 4th quarter. Citadel Advisors LLC now owns 241,797 shares of the company’s stock worth $122,000 after purchasing an additional 183,120 shares during the period. Virtu Financial LLC boosted its stake in Synthetic Biologics by 256.1% in the 4th quarter. Virtu Financial LLC now owns 299,577 shares of the company’s stock worth $152,000 after purchasing an additional 215,440 shares during the period. Blair William & Co. IL boosted its stake in Synthetic Biologics by 14.8% in the 1st quarter. Blair William & Co. IL now owns 1,980,857 shares of the company’s stock worth $631,000 after purchasing an additional 255,096 shares during the period. Finally, 683 Capital Management LLC acquired a new position in Synthetic Biologics in the 4th quarter worth $762,000.
About Synthetic Biologics
Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.